Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

22,168 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T, Perez-Soler R. Li T, et al. Target Oncol. 2009 Apr;4(2):107-19. doi: 10.1007/s11523-009-0114-0. Epub 2009 May 19. Target Oncol. 2009. PMID: 19452131 Review.
Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.
Li T, Ling YH, Perez-Soler R. Li T, et al. J Thorac Oncol. 2008 Jun;3(6):643-7. doi: 10.1097/JTO.0b013e3181753b24. J Thorac Oncol. 2008. PMID: 18520805
The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
Perez-Soler R, Zou Y, Li T, Ling YH. Perez-Soler R, et al. Among authors: li t. Clin Cancer Res. 2011 Nov 1;17(21):6766-77. doi: 10.1158/1078-0432.CCR-11-0545. Epub 2011 Sep 13. Clin Cancer Res. 2011. PMID: 21914790 Retracted.
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Li T, Ling YH, Goldman ID, Perez-Soler R. Li T, et al. Clin Cancer Res. 2007 Jun 1;13(11):3413-22. doi: 10.1158/1078-0432.CCR-06-2923. Clin Cancer Res. 2007. PMID: 17545550
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R. Li T, et al. Clin Lung Cancer. 2017 Jan;18(1):60-67. doi: 10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28. Clin Lung Cancer. 2017. PMID: 27919627 Free PMC article. Clinical Trial.
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R. Li T, et al. Lung Cancer. 2010 Apr;68(1):89-93. doi: 10.1016/j.lungcan.2009.05.009. Epub 2009 Jun 12. Lung Cancer. 2010. PMID: 19524318 Clinical Trial.
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Ling YH, Li T, Perez-Soler R, Haigentz M Jr. Ling YH, et al. Among authors: li t. Cancer Chemother Pharmacol. 2009 Aug;64(3):539-48. doi: 10.1007/s00280-008-0902-8. Epub 2009 Jan 8. Cancer Chemother Pharmacol. 2009. PMID: 19130057
Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
Ling YH, Li T, Yuan Z, Haigentz M Jr, Weber TK, Perez-Soler R. Ling YH, et al. Among authors: li t. Mol Pharmacol. 2007 Aug;72(2):248-58. doi: 10.1124/mol.107.034827. Epub 2007 Apr 24. Mol Pharmacol. 2007. PMID: 17456787 Retracted.
Inhibiting Ras signaling in the therapy of breast cancer.
Li T, Sparano JA. Li T, et al. Clin Breast Cancer. 2003 Feb;3(6):405-16; discussion 417-20. doi: 10.3816/CBC.2003.n.005. Clin Breast Cancer. 2003. PMID: 12636885 Review.
Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer.
Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV, Danenberg KD. Gandara DR, et al. Among authors: li t. J Thorac Oncol. 2010 Dec;5(12):1933-8. doi: 10.1097/JTO.0b013e3181fd418d. J Thorac Oncol. 2010. PMID: 20975603
22,168 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback